Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New PET tracers aim to spot tau tangles in rare brain disease

NCT ID NCT07348276

Diagnosis Sponsor: Invicro Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This early-phase study tests two new imaging drugs, [18F]ABBV-964i and [18F]ABBV-965i, designed to light up tau protein buildup in the brain during a PET scan. Tau buildup is linked to Progressive Supranuclear Palsy (PSP), a rare movement and thinking disorder. The trial includes up to 24 adults (healthy volunteers and people with PSP) to check safety, radiation exposure, and how well the drugs show tau in the brain. Better imaging could help diagnose PSP earlier and track disease progression.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
[18F]ABBV-964i and [18F]ABBV-965i (imaging drugs used in PET scans)
What this could lead to
If successful, these imaging drugs could help doctors see tau buildup in the brain, leading to earlier and more accurate diagnosis of PSP and better tools for tracking the disease.
What could go wrong
This is a very early, small study (24 people) focused on safety and imaging quality, not treatment. The drugs may not work as hoped, and results may not apply to larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

11 people

The number who actually took part.

Started

Nov 2025

Finished

Mar 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Males or females: PSP 40-80 years; HV 18-80 years * Body weight: 43-120 kg (95-265 lb) * Women of childbearing potential: abstinent or use 2 contraception methods (one barrier) during study and 30 days post last injection * Men: use 2 contraception methods and refrain from sperm donation during study and 90 days post last injection * Adequate circulation and normal clotting for arterial cannulation * Sufficient mobility and ability to lie still for imaging * Healthy Volunteers: informed consent, no clinically relevant findings, no cognitive impairment * PSP Participants: informed consent or assent with LAR consent, clinical diagnosis per NINDS-SPSP criteria, MRI consistent with PSP, able to ambulate, tolerate MRI, comply with study procedures, caregiver available if needed Exclusion Criteria: * History of drug or alcohol abuse in past 12 months * Clinically significant lab abnormalities or unstable illness * Investigational drug/device use within 30 days * Pregnant, lactating, or breastfeeding * Significant comorbid conditions (GI, CV, hepatic, renal, etc.) * Abnormal clotting parameters (if arterial sampling) * MRI contraindications (implants, claustrophobia) for PSP participants * Use of OTC meds or supplements within 2 weeks (healthy volunteers) * Use of anti-hemostasis meds within 2 weeks of arterial line placement for PSP participants * Unable to lie still for 90 minutes * Major surgery or significant blood loss within 4 weeks * Positive for Hepatitis B, Hepatitis C, or HIV * Deemed unsuitable by Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy participants are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Pick disease progressive supranuclear palsy tauopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy participants Progressive supranuclear palsy (PSP)

Contacts and locations

Locations

  • Invicro (dba Perceptive)

    New Haven, Connecticut, 06510, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.